Get started
Author

Thomas M. Wengenack

Defects in Mitochondrial Dynamics and Metabolomic Signatures of Evolving Energetic Stress in Mouse Models of Familial Alzheimer's Disease
2012 · Eugenia Trushina, Emirhan Nemutlu, et al. · PLoS ONE · 266
PDF
Molecular Targeting of Alzheimer's Amyloid Plaques for Contrast-Enhanced Magnetic Resonance Imaging
2002 · Joseph F. Poduslo, Thomas M. Wengenack, et al. · Neurobiology of Disease · 215
In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent
2004 · Clifford R. Jack, Michael Garwood, et al. · Magnetic Resonance in Medicine · 199
PDF
Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy
2005 · Malgorzata Marjanska, Geoffrey L. Curran, et al. · Proceedings of the National Academy of Sciences · 198
Selective Vulnerability and Early Progression of Hippocampal CA1 Pyramidal Cell Degeneration and GFAP-Positive Astrocyte Reactivity in the Rat Four-Vessel Occlusion Model of Transient Global Ischemia
1993 · J.M. Ordy, T.M. Wengenack, et al. · Experimental Neurology · 154
In VivoMagnetic Resonance Microimaging of Individual Amyloid Plaques in Alzheimer's Transgenic Mice
2005 · Clifford R. Jack, Thomas M. Wengenack, et al. · Journal of Neuroscience · 148
PDF
Permeability of Proteins at the Blood–Brain Barrier in the Normal Adult Mouse and Double Transgenic Mouse Model of Alzheimer's Disease
2001 · Joseph F. Poduslo, Geoffry L. Curran, et al. · Neurobiology of Disease · 121
Quantitative histological analysis of amyloid deposition in Alzheimer’s double transgenic mouse brain
2000 · T.M Wengenack, S Whelan, et al. · Neuroscience · 99
Camstatins Are Peptide Antagonists of Calmodulin Based Upon a Conserved Structural Motif in PEP-19, Neurogranin, and Neuromodulin
1996 · J. Randall Slemmon, James I. Morgan, et al. · Journal of Biological Chemistry · 94
PDF
In vivo targeting of antibody fragments to the nervous system for Alzheimer’s disease immunotherapy and molecular imaging of amyloid plaques
2007 · Joseph F. Poduslo, Muthu Ramakrishnan, et al. · Journal of Neurochemistry · 89
Targeting Alzheimer amyloid plaques in vivo
2000 · Thomas M. Wengenack, Geoffry L. Curran, et al. · Nature Biotechnology · 88
Design and Chemical Synthesis of a Magnetic Resonance Contrast Agent with Enhancedin VitroBinding, High Blood−Brain Barrier Permeability, andin VivoTargeting to Alzheimer's Disease Amyloid Plaques
2004 · Joseph F. Poduslo, Geoffry L. Curran, et al. · Biochemistry · 79
Magnetic Resonance Imaging of Alzheimer's Pathology in the Brains of Living Transgenic Mice: A New Tool in Alzheimer's Disease Research
2007 · Clifford R. Jack, Malgorzata Marjanska, et al. · The Neuroscientist · 77
Surface Plasmon Resonance Binding Kinetics of Alzheimer’s Disease Amyloid β Peptide-Capturing and Plaque-Binding Monoclonal Antibodies
2009 · Muthu Ramakrishnan, Karunya K. Kandimalla, et al. · Biochemistry · 75
Activation of programmed cell death markers in ventral horn motor neurons during early presymptomatic stages of amyotrophic lateral sclerosis in a transgenic mouse model
2004 · Thomas M. Wengenack, Silvina S. Holasek, et al. · Brain Research · 66
Targeting Vascular Amyloid in Arterioles of Alzheimer Disease Transgenic Mice With Amyloid β Protein Antibody-Coated Nanoparticles
2011 · Joseph F. Poduslo, Kristi L. Hultman, et al. · Journal of Neuropathology & Experimental Neurology · 64
PDF
Activation of the stress-activated MAP kinase, p38, but not JNK in cortical motor neurons during early presymptomatic stages of amyotrophic lateral sclerosis in transgenic mice
2005 · Silvina S. Holasek, Thomas M. Wengenack, et al. · Brain Research · 63
Comparison of amyloid plaque contrast generated by T2‐weighted, T‐weighted, and susceptibility‐weighted imaging methods in transgenic mouse models of Alzheimer's disease
2009 · Ryan Chamberlain, Denise Reyes, et al. · Magnetic Resonance in Medicine · 62
Pharmacokinetic Analysis of the Blood-Brain Barrier Transport of 125I-Amyloid β Protein 40 in Wild-Type and Alzheimer’s Disease Transgenic Mice (APP,PS1) and Its Implications for Amyloid Plaque Formation
2005 · Karunya K. Kandimalla, Geoffry L. Curran, et al. · Journal of Pharmacology and Experimental Therapeutics · 60
A Carrier for Non-Covalent Delivery of Functional Beta-Galactosidase and Antibodies against Amyloid Plaques and IgM to the Brain
2011 · Gobinda Sarkar, Geoffry L. Curran, et al. · PLoS ONE · 59
PDF
Mutant mice with small amounts of BubR1 display accelerated age-related gliosis
2006 · Tyler K. Hartman, Thomas M. Wengenack, et al. · Neurobiology of Aging · 54
Selective Contrast Enhancement of Individual Alzheimer’s Disease Amyloid Plaques Using a Polyamine and Gd-DOTA Conjugated Antibody Fragment Against Fibrillar Aβ42 for Magnetic Resonance Molecular Imaging
2008 · Muthu Ramakrishnan, Thomas M. Wengenack, et al. · Pharmaceutical Research · 48
Reduced Membrane Lipids in the Cortex of Alzheimer’s Disease Transgenic Mice
2008 · Jeffrey K. Yao, Thomas M. Wengenack, et al. · Neurochemical Research · 48
Postischemic, systemic administration of polyamine-modified superoxide dismutase reduces hippocampal CA1 neurodegeneration in rat global cerebral ischemia
1997 · Thomas M Wengenack, Geoffry L Curran, et al. · Brain Research · 45
Molecular targeting of Alzheimer's amyloid plaques for contrast‐enhanced magnetic resonance imaging
2002 · J. F. Poduslo, T. M. Wengenack, et al. · Journal of Neurochemistry · 43
Works count: 60
Citation count: 2,817
H-index: 28
I10-index: 36
Year
Topic
Type